Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Prostate and Urothelial Cancers

7 Feb 2020

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical activity of PARP inhibitors. Numerous clinical trials with either PARP monotherapy or in combination with other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32117762
DOI: 10.3389/fonc.2020.00114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Prostate and Urothelial CancersPMID 32117762Read ↗

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.Semantic proximity Read ↗

PARP inhibitors in castration-resistant prostate cancerSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read ↗

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trialsSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignanciesSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.